TriSalus Life Sciences, Inc. (TLSI)
4.97
-0.17
(-3.31%)
USD |
NASDAQ |
Sep 03, 15:33
TriSalus Life Sciences Gross Profit Margin (Quarterly) : 86.78% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 86.78% |
| March 31, 2026 | 86.18% |
| December 31, 2025 | 86.66% |
| September 30, 2025 | 83.52% |
| June 30, 2025 | 83.93% |
| March 31, 2025 | 81.80% |
| December 31, 2024 | 82.94% |
| September 30, 2024 | 84.04% |
| Date | Value |
|---|---|
| June 30, 2024 | 84.98% |
| March 31, 2024 | 83.78% |
| December 31, 2023 | 86.44% |
| September 30, 2023 | 85.65% |
| June 30, 2023 | 80.25% |
| March 31, 2023 | 71.65% |
| December 31, 2022 | 74.71% |
| September 30, 2022 | 70.61% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 90.81% |
| Alnylam Pharmaceuticals, Inc. | 76.88% |
| Anika Therapeutics, Inc. | 65.15% |
| Savara, Inc. | -- |
| Vericel Corp. | 72.82% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Assets | -57.22% |
| Return on Invested Capital | -127.7% |
| Profit Margin (Quarterly) | -80.54% |
| Operating Margin (Quarterly) | -86.03% |
| Return on Net Operating Assets | -193.6% |